Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092287
Status:
TERMINATED
Last Update Posted:
2020-04-30
First Post:
2004-09-22
Brief Title:
Comparison of Lanreotide Autogel and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
A Phase III Prospective Multicenter Randomized Open Parallel Group Comparison of Lanreotide Autogel 90 and 120 mg Administered by Deep Subcutaneous Injection Every Four Weeks With Sandostatin LAR Depot 20 and 30 mg Administered by Intramuscular Injection Every Four Weeks for Six Months in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Status:
TERMINATED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-001091-40 | EUDRACT_NUMBER | None | None |